Market revenue in 2022 | USD 99.5 million |
Market revenue in 2030 | USD 128.2 million |
Growth rate | 3.2% (CAGR from 2022 to 2030) |
Largest segment | Beta-adrenergic bronchodilators |
Fastest growing segment | Beta-Adrenergic Bronchodilators |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives |
Key market players worldwide | GSK PLC, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Mylan, Merck KGaA, Merck & Co Inc, Novartis AG ADR, Boehringer Ingelheim, Sun Pharmaceutical Industries, Glenmark Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bronchodilators market will help companies and investors design strategic landscapes.
Beta-adrenergic bronchodilators was the largest segment with a revenue share of 41.11% in 2022. Horizon Databook has segmented the UAE bronchodilators market based on beta-adrenergic bronchodilators, anticholinergic bronchodilators, xanthine derivatives covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE bronchodilators market, including forecasts for subscribers. This country databook contains high-level insights into UAE bronchodilators market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account